Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy

Abstract

CP1 is an uropathogenic Escherichia coli previously shown to promote inflammation and progression to prostate cancer. Here the authors show that in the context of a fully developed prostate cancer, CP1 promotes T cell infiltration into the tumour and increases the efficacy of anti-PD1 immunotherapy.